LOS ANGLES, Sept. 20 (Xinhua) -- A trial of a preventive HIV vaccine candidate has begun enrollment in the United States and South Africa, according to the U.S. National Institutes of Health (NIH).
The Phase 1 trial will evaluate a novel vaccine known as VIR-1388 for its safety and ability to induce an HIV-specific immune response in people, the NIH said in a release.
